Role of heat shock factors (Hsfs) in tumorigenesis
热休克因子(Hsfs)在肿瘤发生中的作用
基本信息
- 批准号:8632076
- 负责人:
- 金额:$ 27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-03-01 至 2018-11-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Lymphocytic LeukemiaAdult Acute Lymphocytic LeukemiaApoptosisApoptoticBone MarrowCell AgingCell DeathCell LineCell LineageCellsCre-LoxPDNA DamageDataDevelopmentDiseaseDisease remissionDoseElderlyExcisionExhibitsFamily memberFrequenciesGenesGenetic TranscriptionGrantHeat shock factorHeat-Shock ResponseHumanIn VitroIncidenceIntrinsic factorIonizing radiationLeadMalignant NeoplasmsMature T-LymphocyteModelingMolecularMolecular BiologyMusMutationNamesPatientsPediatricsPharmaceutical PreparationsPopulationPrimary NeoplasmProcessProliferatingRNA SequencesRadiationRecurrent diseaseRelapseResearch DesignResistance developmentRoleSignal TransductionSpecificityStem cellsSystemT-Cell DevelopmentT-LymphocyteTP53 geneTestingTherapeuticToxic effectTransplantationTreatment outcomeTumor BurdenTumor Suppressor GenesXenobasechemotherapycohortdesignefficacy testingexome sequencinggenome-wideheat shock transcription factorimprovedin vivoinhibitor/antagonistleukemiamouse modelmutantneoplastic cellnew therapeutic targetoutcome forecastprogenitorprotective effectpublic health relevancerepairedresearch studyresponsesmall hairpin RNAtumorigenesis
项目摘要
Acute lymphoblastic leukemia (T-ALL) originates from the T cell lineage. The disease
represents 15% of pediatrics and 25% of adult ALL cases annually, making it the most common
cancer in the very young and elderly populations. Disease relapse occurs frequently, and more
than 80% of the relapse T-ALL cases harbor the TP53 mutation. These patients develop
resistance to chemotherapy that is associated with very poor prognosis. Furthermore, those
patients who do go into remission are faced with severe complications due to their prior
aggressive chemotherapy. It is therefore critical to understand the molecular mechanisms that
cause and drive T-ALL in order to discover novel therapeutic targets with better specificity and
reduced toxicity. Patients with primary and relapse T-ALLs as well as mice with radiation-
induced T-ALL have a very high incidence of activated Notch1 and the TP53 mutation. Indeed,
TP53-deficient mice exhibit a 70% incidence of ALLs, suggesting that this is a good model for
investigating the biology and molecular mechanisms of T-ALL. We have found that deletion of
heat shock factors (Hsfs) Hsf4, Hsf2, or Hsf1 in TP53-deficient mice leads to significant
protection against development of T-ALL. These data suggest that therapeutic inhibition of Hsfs
could be a key to eliminating T-ALL. In this grant, we have designed studies to test the efficacy
of hsf deletion in mouse models of T-ALL and track the genome-wide shift in transcription from
bone marrow (BM) hemopoietic stem cells (HSCs) to thymic progenitors to mature T cells.
Finally, we will examine whether reducing Hsf expression levels in human T-ALL cell lines and
primary tumor cells in vitro or inducible deletion of Hsfs in T-ALL-bearing mice will be a good
therapeutic option for T-ALLs. We hypothesize that Hsfs are not essential for T cell
development; however, they cooperate with oncogenes and tumor suppressor genes to control
T-ALL development, and depletion of Hsfs result in the inability of T-ALL cells to survive. Aim 1
will determine the efficacy of Hsf deletion in mouse models of T-ALL using ionizing radiation
(IR)- or mutant Pten-, induced T-ALLs. In Aim 2 we will determine the molecular mechanisms
underlying Hsf deletion in mouse models of T-ALL and will assess global transcriptional
changes during T cell development in the presence or absence of hsfs and TP53 genes using
RNA sequencing. Exome sequencing of HSCs following IR that will reveal profile mutations that
are eliminated when Hsfs are deleted. In Aim 3 we will assess if the depletion of Hsfs from
human or mouse primary tumors or T-ALL cell lines leads to tumor cell death.
急性淋巴细胞白血病(T- all)起源于T细胞谱系。这种疾病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAHID F MIVECHI其他文献
NAHID F MIVECHI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAHID F MIVECHI', 18)}}的其他基金
Role of heat shock transcription factors (HSFs) in hematological malignancies
热休克转录因子(HSF)在血液恶性肿瘤中的作用
- 批准号:
10568307 - 财政年份:2023
- 资助金额:
$ 27万 - 项目类别:
Regulation and Function of Mammalian HSF4 in vivo
哺乳动物 HSF4 体内的调控和功能
- 批准号:
7842497 - 财政年份:2008
- 资助金额:
$ 27万 - 项目类别:
Regulation and Function of Mammalian HSF4 in vivo
哺乳动物 HSF4 体内的调控和功能
- 批准号:
8072719 - 财政年份:2008
- 资助金额:
$ 27万 - 项目类别:
Regulation and Function of Mammalian HSF4 in vivo
哺乳动物 HSF4 体内的调控和功能
- 批准号:
8277836 - 财政年份:2008
- 资助金额:
$ 27万 - 项目类别:
Regulation and Function of Mammalian HSF4 in vivo
哺乳动物 HSF4 体内的调控和功能
- 批准号:
7665417 - 财政年份:2008
- 资助金额:
$ 27万 - 项目类别:
HSF-4 IS A TRANSCRIPTIONAL REPRESSOR OF HSF-1
HSF-4 是 HSF-1 的转录抑制子
- 批准号:
6362756 - 财政年份:2000
- 资助金额:
$ 27万 - 项目类别:














{{item.name}}会员




